#BEGIN_DRUGCARD DB04367

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H10N5O2

# Chemical_IUPAC_Name:
2-amino-4-{8-oxo-4H,5H,6H,7H,8H-pyrrolo[2,3-c]azepin-4-ylidene}-4,5-dihydro-1H-imidazol-5-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Debromohymenialdisine

# HET_ID:
DBQ

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4367

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
244.2294

# Molecular_Weight_Mono:
244.083449589

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1Z57

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.62

# Predicted_LogS:
-2.7

# Predicted_Water_Solubility:
4.92e-01 g/l

# Primary_Accession_No:
DB04367

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
3037580

# PubChem_Substance_ID:
46505283

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01124

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=N\C(C(=O)N1)=C1/CCNC(=O)c2nccc12

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:15 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
TNK2

# Drug_Target_1_GenBank_ID_Gene:
L13738

# Drug_Target_1_GenBank_ID_Protein:
8850245

# Drug_Target_1_GeneCard_ID:
TNK2

# Drug_Target_1_Gene_Name:
TNK2

# Drug_Target_1_Gene_Sequence:
>3111 bp
ATGCAGCCAGAGGAGGGCACAGGCTGGCTGCTGGAGCTGCTGTCCGAGGTGCAGCTGCAA
CAGTACTTCCTGCGGCTCCGAGATGACCTCAACGTCACCCGCCTGTCCCACTTTGAGTAC
GTCAAGAATGAGGACCTGGAGAAGATCGGCATGGGTCGGCCTGGCCAGCGGCGGCTGTGG
GAGGCTGTGAAGAGGAGGAAGGCCTTGTGCAAACGCAAGTCGTGGATGAGTAAGGTGTTC
AGTGGAAAGCGACTGGAGGCTGAGTTCCCACCTCATCACTCTCAGAGCACCTTCCGGAAG
ACCTCGCCCGCCCCTGGGGGCCCAGCAGGGGAGGGGCCCCTGCAGAGCCTCACCTGCCTC
ATTGGGGAGAAGGACCTGCGCCTCCTGGAGAAGCTGGGTGATGGTTCCTTTGGCGTGGTG
CGCAGGGGCGAGTGGGACGCGCCCTCAGGGAAGACGGTGAGTGTGGCTGTGAAGTGCCTG
AAGCCCGATGTCCTGAGCCAGCCAGAAGCCATGGACGACTTCATCCGGGAGGTCAATGCC
ATGCACTCGCTCGACCACCGAAACCTCATCCGCCTCTACGGGGTGGTGCTCACGCCGCCC
ATGAAGATGGTGACAGAGCTGGCACCTCTGGGATCGTTGTTGGACCGGCTACGTAAGCAC
CAGGGCCACTTCCTCCTGGGGACTCTGAGCCGCTACGCTGTGCAGGTGGCTGAGGGCATG
GGCTACCTGGAGTCCAAGCGCTTTATTCACCGTGACCTGGCTGCCCGCAATCTGCTGTTG
GCTACCCGCGACCTGGTCAAGATCGGGGACTTTGGGCTGATGCGAGCACTACCTCAGAAT
GACGACCATTACGTCATGCAGGAACATCGCAAGGTGCCCTTCGCCTGGTGTGCCCCCGAG
AGCCTGAAGACACGCACCTTCTCCCATGCCAGCGACACCTGGATGTTCGGGGTGACACTG
TGGGAAATGTTCACCTACGGCCAGGAGCCCTGGATCGGCCTCAACGGCAGTCAGATCCTG
CATAAGATCGACAAGGAGGGGGAGCGGCTGCCCCGGCCCGAGGACTGTCCCCAGGACATC
TACAACGTCATGGTCCAGTGCTGGGCTCACAAGCCAGAGGACAGACCCACGTTTGTGGCC
CTGCGGGACTTCCTGCTGGAGGCCCAGCCCACAGACATGCGGGCCCTTCAGGACTTTGAG
GAACCGGACAAGCTGCACATCCAGATGAATGATGTCATCACCGTCATCGAGGGAAGGGCC
GAGAACTACTGGTGGCGTGGCCAGAACACACGGACGCTGTGTGTGGGGCCCTTCCCTCGC
AACGTGGTGACCTCCGTGGCCGGCCTGTCGGCCCAGGACATCAGCCAGCCCCTGCAGAAC
AGCTTCATCCACACAGGGCATGGCGACAGTGACCCCCGCCACTGCTGGGGCTTCCCGGAC
AGGATTGACGAACTGTATCTGGGAAACCCCATGGACCCCCCCGACCTCCTGAGCGTGGAA
CTGAGCACCTCCCGGCCCCCCCAGCATCTAGGAGGGGTGAAAAAACCAACCTATGACCCT
GTGAGCGAGGACCAAGACCCCTTGTCCAGCGACTTCAAGAGGCTGGGCCTGCGGAAGCCA
GGCCTGCCCCGAGGGCTGTGGCTGGCGAAGCCCTCGGCGCGGGTGCCGGGCACCAAGGCC
AGCCGAGGCAGCGGGGCTGAGGTCACGCTCATCGACTTCGGTGAGGAGCCCGTGGTCCCG
GCCCTACGGCCCTGCCCGCCCTCCCTGGCGCAGCTGGCCATGGACGCCTGCTCCCTGCTG
GACGAGACCCCGCCTCAGAGCCCCACGCGGGCACTGCCCCGGCCCCTGCACCCCACGCCT
GTGGTGGACTGGGACGCACGCCCGCTGCCCCCCCCGCCCGCCTATGACGACGTGGCCCAG
GATGAGGATGACTTTGAGATCTGCTCCATCAACAGCACCCTCGTGGGCGCGGGGGTCCCT
GCCGGGCCCAGCCAGGGCCAGACCAACTACGCCTTTGTGCCTGAGCAGGCGCGGCCGCCC
CCTCCCCTGGAGGACAACCTGTTCCTCCCGCCCCAGGGTGGGGGCAAGCCGCCCAGCTCC
GCACAGACCGCAGAGATCTTCCAGGCGCTACAGCAGGAGTGCATGAGGCAACTGCAGGCT
CCGGGCTCCCCGGCCCCCTCTCCCAGCCCGGGGGGTGACGACAAGCCCCAGGTGCCTCCT
CGGGTACCCATCCCCCCTCGGCCCACGCGCCCACACGTCCAGCTGTCTCCAGCCCCCCCG
GGCGAGGAGGAGACCAGCCAGTGGCCTGGACCTGCTTCCCCTCCCCGGGTGCCTCCGCGG
GAGCCCCTGTCCCCTCAAGGCTCGAGGACACCCAGCCCCCTGGTACCACCTGGCAGCTCC
CCGCTGCCACCCCGGCTCTCAAGCTCACCTGGGAAGACCATGCCCACCACCCAGAGCTTT
GCCTCAGACCCCAAGTACGCCACCCCCCAGGTGATCCAGGCCCCTGGCGCGGGTGGTCCC
TGCATCCTGCCCATCGTCCGGGATGGCAAGAAGGTCAGCAGCACCCACTATTACTTGCTG
CCCGAGCGACCATCCTACCTGGAGCGCTACCAGCGCTTCCTGCGTGAGGCCCAGAGCCCC
GAGGAGCCTACCCCCCTGCCTGTGCCTCTGCTGCTGCCCCCACCCAGCACCCCAGCCCCC
GCCGCCCCCACGGCCACCGTGCGGCCGATGCCCCAGGCTGCCTTGGACCCCAAGGCCAAC
TTCTCCACCAACAACAGCAACCCAGGGGCCCGGCCACCACCCCCGAGGGCCACTGCTCGG
CTGCCACAGAGGGGCTGCCCTGGCGATGGGCCAGAGGCGGGCCGGCCAGCAGACAAGATC
CAGATGGCCATGGTGCATGGGGTGACCACAGAGGAGTGCCAGGCGGCCCTGCAGTGCCAC
GGCTGGAGCGTGCAGAGGGCTGCCCAGTATCTGAAGGTGGAGCAGCTCTTCGGGCTGGGT
CTGCGGCCCAGAGGGGAGTGCCACAAAGTGCTGGAGATGTTCGACTGGAACCTGGAGCAG
GCCGGCTGCCACCTTCTGGGCTCCTGGGGCCCTGCCCACCACAAGCGCTGA

# Drug_Target_1_General_Function:
Involved in protein kinase activity

# Drug_Target_1_General_References:
10360579	Mott HR, Owen D, Nietlispach D, Lowe PN, Manser E, Lim L, Laue ED: Structure of the small G protein Cdc42 bound to the GTPase-binding domain of ACK. Nature. 1999 May 27;399(6734):384-8.
12522270	Salomon AR, Ficarro SB, Brill LM, Brinker A, Phung QT, Ericson C, Sauer K, Brock A, Horn DM, Schultz PG, Peters EC: Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):443-8. Epub 2003 Jan 9.
8497321	Manser E, Leung T, Salihuddin H, Tan L, Lim L: A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature. 1993 May 27;363(6427):364-7.

# Drug_Target_1_HGNC_ID:
HGNC:19297

# Drug_Target_1_HPRD_ID:
06104

# Drug_Target_1_ID:
849

# Drug_Target_1_Locus:
3q29

# Drug_Target_1_Molecular_Weight:
114328

# Drug_Target_1_Name:
Activated CDC42 kinase 1

# Drug_Target_1_Number_of_Residues:
1036

# Drug_Target_1_PDB_ID:
1U54

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00018	SH3_1
PF07714	Pkinase_Tyr

# Drug_Target_1_Protein_Sequence:
>Activated CDC42 kinase 1
MQPEEGTGWLLELLSEVQLQQYFLRLRDDLNVTRLSHFEYVKNEDLEKIGMGRPGQRRLW
EAVKRRKALCKRKSWMSKVFSGKRLEAEFPPHHSQSTFRKTSPAPGGPAGEGPLQSLTCL
IGEKDLRLLEKLGDGSFGVVRRGEWDAPSGKTVSVAVKCLKPDVLSQPEAMDDFIREVNA
MHSLDHRNLIRLYGVVLTPPMKMVTELAPLGSLLDRLRKHQGHFLLGTLSRYAVQVAEGM
GYLESKRFIHRDLAARNLLLATRDLVKIGDFGLMRALPQNDDHYVMQEHRKVPFAWCAPE
SLKTRTFSHASDTWMFGVTLWEMFTYGQEPWIGLNGSQILHKIDKEGERLPRPEDCPQDI
YNVMVQCWAHKPEDRPTFVALRDFLLEAQPTDMRALQDFEEPDKLHIQMNDVITVIEGRA
ENYWWRGQNTRTLCVGPFPRNVVTSVAGLSAQDISQPLQNSFIHTGHGDSDPRHCWGFPD
RIDELYLGNPMDPPDLLSVELSTSRPPQHLGGVKKPTYDPVSEDQDPLSSDFKRLGLRKP
GLPRGLWLAKPSARVPGTKASRGSGAEVTLIDFGEEPVVPALRPCPPSLAQLAMDACSLL
DETPPQSPTRALPRPLHPTPVVDWDARPLPPPPAYDDVAQDEDDFEICSINSTLVGAGVP
AGPSQGQTNYAFVPEQARPPPPLEDNLFLPPQGGGKPPSSAQTAEIFQALQQECMRQLQA
PGSPAPSPSPGGDDKPQVPPRVPIPPRPTRPHVQLSPAPPGEEETSQWPGPASPPRVPPR
EPLSPQGSRTPSPLVPPGSSPLPPRLSSSPGKTMPTTQSFASDPKYATPQVIQAPGAGGP
CILPIVRDGKKVSSTHYYLLPERPSYLERYQRFLREAQSPEEPTPLPVPLLLPPPSTPAP
AAPTATVRPMPQAALDPKANFSTNNSNPGARPPPPRATARLPQRGCPGDGPEAGRPADKI
QMAMVHGVTTEECQAALQCHGWSVQRAAQYLKVEQLFGLGLRPRGECHKVLEMFDWNLEQ
AGCHLLGSWGPAHHKR

# Drug_Target_1_Reaction:
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Tyrosine kinase, that after binding to CDC42, inhibits both its intrinsic and stimulated GTPase activity

# Drug_Target_1_SwissProt_ID:
Q07912

# Drug_Target_1_SwissProt_Name:
ACK1_HUMAN

# Drug_Target_1_Synonyms:
ACK-1
EC 2.7.10.2
Tyrosine kinase non- receptor protein 2

# Drug_Target_1_Theoretical_pI:
7.17

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Nucleus

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CLK1

# Drug_Target_2_GenBank_ID_Gene:
L29219

# Drug_Target_2_GenBank_ID_Protein:
632964

# Drug_Target_2_GeneCard_ID:
CLK1

# Drug_Target_2_Gene_Name:
CLK1

# Drug_Target_2_Gene_Sequence:
>1455 bp
ATGAGACACTCAAAGAGAACTTACTGTCCTGATTGGGATGACAAGGATTGGGATTATGGA
AAATGGAGGAGCAGCAGCAGTCATAAAAGAAGGAAGAGATCACATAGCAGTGCCCAGGAG
AACAAGCGCTGCAAATACAATCACTCTAAAATGTGTGATAGCCATTATTTGGAAAGCAGG
TCTATAAATGAGAAAGATTATCATAGTCGACGCTACATTGATGAGTACAGAAATGACTAC
ACTCAAGGATGTGAACCTGGACATCGCCAAAGAGACCATGAAAGCCGGTATCAGAACCAT
AGTAGCAAGTCTTCTGGTAGAAGTGGAAGAAGTAGTTATAAAAGCAAACACAGGATTCAC
CACAGTACTTCACATCGTCGTTCACATGGGAAGAGTCACCGAAGGAAAAGAACCAGGAGT
GTAGAGGATGATGAGGAGGGTCACCTGATCTGTCAGAGTGGAGACGTACTAAGTGCAAGA
TATGAAATTGTTGATACTTTAGGTGAAGGAGCTTTTGGAAAAGTTGTGGAGTGCATCGAT
CATAAAGCGGGAGGTAGACATGTAGCAGTAAAAATAGTTAAAAATGTGGATAGATACTGT
GAAGCTGCTCGCTCAGAAATACAAGTTCTGGAACATCTGAATACAACAGACCCCAACAGT
ACTTTCCGCTGTGTCCAGATGTTGGAATGGTTTGAGCATCATGGTCACATTTGCATTGTT
TTTGAACTATTGGGACTTAGTACTTACGACTTCATTAAAGAAAATGGTTTTCTACCATTT
CGACTGGATCATATCAGAAAGATGGCATATCAGATATGCAAGTCTGTGAATTTTTTGCAC
AGTAATAAGTTGACTCACACAGACTTAAAGCCTGAAAACATCTTATTTGTGCAGTCTGAC
TACACAGAGGCGTATAATCCCAAAATAAAACGTGATGAACGCACCTTAATAAATCCAGAT
ATTAAAGTTGTAGACTTTGGTAGTGCAACATATGATGACGAACATCACAGTACATTGGTA
TCTACAAGACATTATAGAGCACCTGAAGTTATTTTAGCCCTAGGGTGGTCCCAACCATGT
GATGTCTGGAGCATAGGATGCATTCTTATTGAATACTATCTTGGGTTTACCGTATTTCCA
ACACACGATAGTAAGGAGCATTTAGCAATGATGGAAAGGATTCTTGGACCTCTACCAAAA
CATATGATACAGAAAACCAGGAAACGTAAATATTTTCACCACGATCGATTAGACTGGGAT
GAACACAGTTCTGCCGGCAGATATGTTTCAAGAGCCTGTAAACCTCTGAAGGAATTTATG
CTTTCTCAAGATGTTGAACATGAGCGTCTCTTTGACCTCATTCAGAAAATGTTGGAGTAT
GATCCAGCCAAAAGAATTACTCTCAGAGAAGCCTTAAAGCATCCTTTCTTTGACCTTCTG
AAGAAAAGTATATAG

# Drug_Target_2_General_Function:
Involved in protein kinase activity

# Drug_Target_2_General_References:
1704889	Johnson KW, Smith KA: Molecular cloning of a novel human cdc2/CDC28-like protein kinase. J Biol Chem. 1991 Feb 25;266(6):3402-7.
7990150	Hanes J, von der Kammer H, Klaudiny J, Scheit KH: Characterization by cDNA cloning of two new human protein kinases. Evidence by sequence comparison of a new family of mammalian protein kinases. J Mol Biol. 1994 Dec 16;244(5):665-72.

# Drug_Target_2_HGNC_ID:
HGNC:2068

# Drug_Target_2_HPRD_ID:
09058

# Drug_Target_2_ID:
3318

# Drug_Target_2_Locus:
2q33

# Drug_Target_2_Molecular_Weight:
57206

# Drug_Target_2_Name:
Dual specificity protein kinase CLK1

# Drug_Target_2_Number_of_Residues:
484

# Drug_Target_2_PDB_ID:
1Z57

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_2_Protein_Sequence:
>Dual specificity protein kinase CLK1
MRHSKRTYCPDWDDKDWDYGKWRSSSSHKRRKRSHSSAQENKRCKYNHSKMCDSHYLESR
SINEKDYHSRRYIDEYRNDYTQGCEPGHRQRDHESRYQNHSSKSSGRSGRSSYKSKHRIH
HSTSHRRSHGKSHRRKRTRSVEDDEEGHLICQSGDVLSARYEIVDTLGEGAFGKVVECID
HKAGGRHVAVKIVKNVDRYCEAARSEIQVLEHLNTTDPNSTFRCVQMLEWFEHHGHICIV
FELLGLSTYDFIKENGFLPFRLDHIRKMAYQICKSVNFLHSNKLTHTDLKPENILFVQSD
YTEAYNPKIKRDERTLINPDIKVVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPC
DVWSIGCILIEYYLGFTVFPTHDSKEHLAMMERILGPLPKHMIQKTRKRKYFHHDRLDWD
EHSSAGRYVSRACKPLKEFMLSQDVEHERLFDLIQKMLEYDPAKRITLREALKHPFFDLL
KKSI

# Drug_Target_2_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex may be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing. Phosphorylates serines, threonines and tyrosines

# Drug_Target_2_SwissProt_ID:
P49759

# Drug_Target_2_SwissProt_Name:
CLK1_HUMAN

# Drug_Target_2_Synonyms:
CDC-like kinase 1
EC 2.7.12.1

# Drug_Target_2_Theoretical_pI:
9.02

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB04367
